Glioblastoma: Emerging Treatments and Novel Trial Designs

Nunno, Vincenzo Di; Franceschi, Enrico; Tosoni, Alicia; Gatto, Lidia; Lodi, Raffaele; Bartolini, Stefania; Brandes, Alba Ariela

doi:10.3390/cancers13153750

Cited by 18 publications

(12 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have found that preoperative or postoperative radiotherapy can improve PFS and OS. 10,23 Cai et al 24 performed Cox analysis of GBM patients treated with temozolomide (TMZ) using TCGA data, and found that patients treated by TMZ combined with radiotherapy could achieve longer survival. Gittleman et al 18 analyzed data of IDH wild-type GBM patients from OBTS and the University of California San Francisco (UCSF) and also found that radiotherapy combined with TMZ increased the likelihood of survival.…”

Section: Treatmentmentioning

confidence: 99%

Nomograms for prognostic risk assessment in glioblastoma multiforme: Applications and limitations

et al. 2022

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common and aggressive form of brain cancer. Prognosis evaluation is of great significance in guiding individualized treatment and monitoring of GBM. By integrating different prognostic variables, nomograms simplify the statistical risk prediction model into numerical estimates for death or recurrence, and are hence widely applied in prognosis prediction. In the past two decades, the application of high-throughput profiling technology and the establishment of TCGA database and other public data deposits have provided opportunities to identify cancer-related molecules and prognostic biomarkers. As a result, both molecular features and clinical characteristics of cancer have been reported to be the key factors in nomogram model construction. This article comprehensively reviewed 35 studies of GBM nomograms, analyzed the present situation of GBM nomograms, and discussed the role and significance of nomograms in personalized risk assessment and clinical treatment decision-making. To facilitate the application of nomograms in the prognostic prediction of GBM patients, a website has been established for the online access of nomograms based on the studies of this review, which is called Consensus Nomogram Spectrum for Glioblastoma (CNSgbm) and is accessible through https://bioinfo.henu.edu.cn/nom/NomList.jsp.

show abstract

Section: Treatmentmentioning

confidence: 99%

Nomograms for prognostic risk assessment in glioblastoma multiforme: Applications and limitations

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The TME offers novel targets for the treatment of malignant gliomas (72)(73)(74). The clinical importance of TME has been largely investigated in GBM (7), while only recently has it been assessed in patients with low-grade gliomas.…”

Section: Therapeutic Implications and Future Developmentsmentioning

confidence: 99%

Tumor-Associated Microenvironment of Adult Gliomas: A Review

et al. 2022

Self Cite

View full text Add to dashboard Cite

The glioma-associated tumor microenvironment involves a multitude of different cells ranging from immune cells to endothelial, glial, and neuronal cells surrounding the primary tumor. The interactions between these cells and glioblastoma (GBM) have been deeply investigated while very little data are available on patients with lower-grade gliomas. In these tumors, it has been demonstrated that the composition of the microenvironment differs according to the isocitrate dehydrogenase status (mutated/wild type), the presence/absence of codeletion, and the expression of specific alterations including H3K27 and/or other gene mutations. In addition, mechanisms by which the tumor microenvironment sustains the growth and proliferation of glioma cells are still partially unknown. Nonetheless, a better knowledge of the tumor-associated microenvironment can be a key issue in the optic of novel therapeutic drug development.

show abstract

“…There are several reasons behind these failures. First, the enrollment of GBM patients within clinical trials is limited only to10% of all GBM patients ( 7 , 8 ).…”

Section: Introductionmentioning

confidence: 99%

Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance

Nunno¹,

Franceschi

Tosoni

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Glioblastoma is an aggressive tumor and is associated with a dismal prognosis. The availability of few active treatments as well as the inexorable recurrence after surgery are important hallmarks of the disease. The biological behavior of glioblastoma tumor cells reveals a very complex pattern of genomic alterations and is partially responsible for the clinical aggressiveness of this tumor. It has been observed that glioblastoma cells can recruit, manipulate and use other cells including neurons, glial cells, immune cells, and endothelial/stromal cells. The final result of this process is a very tangled net of interactions promoting glioblastoma growth and progression. Nonetheless, recent data are suggesting that the microenvironment can also be a niche in which glioblastoma cells can differentiate into glial cells losing their tumoral phenotype. Here we summarize the known interactions between micro-environment and glioblastoma cells highlighting possible therapeutic implications.

show abstract

Glioblastoma: Emerging Treatments and Novel Trial Designs

Cited by 18 publications

References 117 publications

Nomograms for prognostic risk assessment in glioblastoma multiforme: Applications and limitations

Nomograms for prognostic risk assessment in glioblastoma multiforme: Applications and limitations

Tumor-Associated Microenvironment of Adult Gliomas: A Review

Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance

Contact Info

Product

Resources

About